This inventor holds 1 USPTO granted patent. Top assignee: Kainos Medicine Inc.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Jiyoung Min: Innovator in Pharmaceutical Composition
Introduction
Jiyoung Min is a notable inventor based in Seongnam, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in developing compounds that target specific diseases. His innovative work has the potential to impact the treatment of autoimmune diseases and lymphomas.
Latest Patents
Jiyoung Min holds a patent for the compound N-(1H-imidazol-2-yl)benzamide. This compound, along with its pharmaceutically acceptable salts, prodrugs, solvates, or stereoisomers, exhibits excellent inhibitory activity against IRAK-4. This novel compound is designed to be used without side effects, providing an efficient means for the prevention and treatment of diseases mediated by IRAK-4 receptors.
Career Highlights
Currently, Jiyoung Min is associated with Kainos Medicine Inc., where he continues to advance his research and development efforts. His work is characterized by a commitment to creating effective pharmaceutical solutions that address critical health issues.
Collaborations
Jiyoung Min collaborates with talented individuals in his field, including Sunmi Kim and Hanyang Cho. Their combined expertise contributes to the innovative environment at Kainos Medicine Inc.
Conclusion
Jiyoung Min's contributions to pharmaceutical innovation, particularly through his patent on N-(1H-imidazol-2-yl)benzamide, highlight his role as a key inventor in the industry. His work promises to enhance treatment options for patients suffering from autoimmune diseases and lymphomas.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile